Altimmune (ALT) Depreciation & Amortization (CF) (2010 - 2022)
Altimmune (ALT) posted quarterly Depreciation & Amortization (CF) of $23000.0 for Q1 2026, down 20.69% year-over-year from $29000.0 in Q1 2025, and down 11.54% quarter-over-quarter from $26000.0 in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Depreciation & Amortization (CF) (2010 - 2022) Analysis & Trends
Altimmune (ALT) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $23000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 20.69% year-over-year to $23000.0; the TTM figure through Mar 2026 stood at $106000.0 (down 13.11% YoY), while the FY2025 annual figure was $112000.0, down 44.0% from the prior year.
- Depreciation & Amortization (CF) eased to $23000.0 in Q1 2026 per ALT's latest filing, from $26000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $137000.0 in Q4 2023 and bottomed at -$141000.0 in Q3 2022.
- Historically, Depreciation & Amortization (CF) has averaged $54125.0 across 5 years, with a median of $45000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 149.47% — and 2025, when it surged 620.0%.
- Altimmune's Depreciation & Amortization (CF) stood at -$141000.0 in 2022, then soared by 197.16% to $137000.0 in 2023, then sank by 103.65% to -$5000.0 in 2024, then soared by 620.0% to $26000.0 in 2025, then fell by 11.54% to $23000.0 in 2026.
- Business Quant data shows ALT's Depreciation & Amortization (CF) at $23000.0 in Q1 2026, $26000.0 in Q4 2025, and $27000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -141,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 119,000.00 |
| Dec 31, 2021 | 117,301.00 |
| Sep 30, 2021 | 285,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | 74,000.00 |
| Dec 31, 2020 | 209,946.00 |
| Sep 30, 2020 | 72,887.00 |
| Jun 30, 2020 | 72,689.00 |
| Mar 31, 2020 | 73,356.00 |
| Jun 30, 2013 | 41,854.00 |
| Mar 31, 2013 | 52,602.00 |
| Dec 31, 2012 | 69,105.00 |
| Sep 30, 2012 | 72,453.00 |
| Jun 30, 2012 | 76,448.00 |
| Mar 31, 2012 | 85,910.00 |
| Dec 31, 2011 | 112,260.00 |
| Sep 30, 2011 | 114,494.00 |
| Jun 30, 2011 | 116,690.00 |